Analyst Ratings for Intellia Therapeutics (NTLA)
NTLA Rating Summary
NTLA Price Target Summary
- Highest: $106.00 (Brookline Capital Markets)
- Lowest: $5.00 (JPMorgan)
- Average: $25.76
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$25.76 (+125.6%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
Rating Score: 6.3 / 10
Percentile Rank: 66%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/6/2026 | Barclays | Gena Wang | New Coverage | Underweight (N/A) |
8.00 (N/A) |
12.75 (11.42) |
-10.43% | Details |
| 8/6/2026 | Evercore ISI | Jonathan Miller | Upgrade | Outperform (In Line) |
24.00 (16.00) |
10.97 (11.42) |
4.1% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
